CMS Final Rule Bars Federal Funding for Youth Gender-Affirming Care

On August 13, 2026, the Centers for Medicare & Medicaid Services (CMS) issued a final rule that prohibits the use of federal Medicaid funds to pay for “sex-rejecting procedures” (SRPs) for individuals under 18 and bans Children's Health Insurance Program (CHIP) funding for the same services for individuals under 19. The rule takes effect on October 13, 2026. SRPs include puberty-blocking medications, cross-sex hormone therapy, and related surgeries. Federal funding will remain available for minors already receiving SRP-related therapies for a six-month transition period after the effective date; children who have not yet begun treatment will lose coverage unless states provide separate financing.

HIPAA Breach Notification Deadline Starts at Discovery, Not Investigation Completion

The final rule builds on a June 20, 2025 regulation that CMS affirmed in the preamble of its August 15, 2026 final rule. Earlier, on December 24, 2025, CMS finalized several elements of its late-2025 proposed rule, though the Medicare hospital Condition of Participation component remains proposed. One day after publication, on August 14, 2026, the U.S. District Court for the District of Massachusetts vacated a provision that had excluded gender-affirming care from essential health benefits under the Affordable Care Act, finding the Health and Human Services action contrary to the ACA.

HIPAA Breach Notification Deadline Starts at Discovery, Not Investigation Completion

CMS estimates that about 36 million children—nearly half of all U.S. minors—receive health care through Medicaid and CHIP. The rule could disproportionately affect low-income and disabled children who rely on these programs for gender-affirming care. State Medicaid and CHIP agencies must evaluate whether they can create state-only funding streams. Managed-care plans need to review coverage policies and await state guidance. Hospitals and providers with pediatric gender programs are urged to assess billing and compliance practices given heightened enforcement risk. Families of patients currently on hormone therapy have a limited window—up to six months from October 13, 2026—to transition care under remaining federal funding.

HIPAA Breach Notification Deadline Starts at Discovery, Not Investigation Completion

CMS framed the rule as a prohibition on federal financing of SRPs for minors, emphasizing that states retain the authority to allocate separate funds for such services. The August 14 2026 court decision highlighted a legal challenge to the administration’s broader effort to exclude gender-affirming care from ACA-mandated essential health benefits. No further federal guidance has been issued, leaving states to determine the viability of alternative funding mechanisms.

HIPAA Breach Notification Deadline Starts at Discovery, Not Investigation Completion

State Medicaid and CHIP agencies are expected to conduct policy reviews and, where feasible, develop state-only financing before the October 13, 2026 deadline. Providers should prepare for billing adjustments and compliance audits. Families of currently treated minors must arrange care transitions within the six-month grace period. Additional guidance from CMS or state authorities may be issued in the weeks leading up to the effective date.

HIPAA Breach Notification Deadline Starts at Discovery, Not Investigation Completion